PYC Therapeutics Limited

PYC

AU000000PYC7

Biotechnology & Medical Research

Market Closed - Australian S.E. Other stock markets 07:10:23 14/06/2024 BST			5-day change	1st Jan Change
0.105 ^AUD	0.00%		-4.55%	-4.55%

06-07	PYC Therapeutics's Fourth Neurodevelopmental Disorder Drug Candidate Moves Closer to Human Trials; Shares Up 5%	MT
05-24	PYC Therapeutics Secures US FDA Orphan Drug Designation for Eye Disease Medication Candidate; Shares Fall 4%	MT

Phylogica Ltd Appoints Dr. Bernard Hockings as Director

January 23, 2014 at 10:53 pm

Phylogica Ltd. announced appointment of Dr. Bernard Hockings as a director. Dr. Hockings is a cardiologist in Perth and became a substantial shareholder in August 2012.

Latest news about PYC Therapeutics Limited

PYC Therapeutics's Fourth Neurodevelopmental Disorder Drug Candidate Moves Closer to Human Trials; Shares Up 5%	06-07	MT
PYC Therapeutics Secures US FDA Orphan Drug Designation for Eye Disease Medication Candidate; Shares Fall 4%	05-24	MT
PYC Therapeutics Completes Dosing for Eye Disease Trial; Shares Fall 5%	05-16	MT
Transcript : PYC Therapeutics Limited - Special Call	05-09
Australian Shares Rebound Amid Easing Middle East Tensions, Ahead of Local Inflation Data	04-22	MT
PYC Therapeutics Confirms Safety, Tolerability of Kidney Medication in Animal Study	04-22	MT
PYC Therapeutics Raises AU$13.5 Million via Retail Offer; AU$21.2 Million Retail Shortfall Placement Announced	04-10	MT
PYC Therapeutics Raises AU$40 Million via Entitlement Offer	03-18	MT
PYC Therapeutics to Raise Up to AU$75 Million for Advancing Drug Candidates	03-14	MT
PYC Therapeutics Limited Reports Earnings Results for the Half Year Ended December 31, 2023	02-29	CI
PYC Therapeutics Receives AU$4.5 Million Upfront Fee for Drug Discovery Collaboration	02-16	MT
Transcript : PYC Therapeutics Limited - Special Call	02-02
PYC Therapeutics to Launch Google Cloud-Hosted Drug Discovery Project; Shares Fall 5%	01-02	MT
Transcript : PYC Therapeutics Limited - Shareholder/Analyst Call	11-24
Transcript : PYC Therapeutics Limited - Special Call	11-17
Pyc Therapeutics Announces the Results of A Study Conducted in Human 3-Dimensional Models Derived from Patients with End-Stage Renal Failure Due to Autosomal Dominant Polycystic Kidney Disease	11-13	CI
PYC Therapeutics Completes Dosing in Second Patient Cohort for Retinitis Pigmentosa Clinical Trial	11-03	MT
PYC Reports Positive Results from Preclinical Studies of Rare Eye Disease Drug	05/10/23	MT
Transcript : PYC Therapeutics Limited - Special Call	04/10/23
PYC Therapeutics Advances to Second Dose Cohort of Phase 1 Trial Following Safety Clearance	22/09/23	MT
PYC Therapeutics Limited Reports Earnings Results for the Full Year Ended June 30, 2023	31/08/23	CI
PYC Therapeutics Limited Announces US FDA Designates PYC's Lead as a Fast Track Development Program	11/08/23	CI
PYC Therapeutics Raises Vision Pharma Shareholding to 96.2%	10/08/23	MT
PYC Therapeutics' RP11 Investigational Drug Candidate Secures Fast Track Designation from US FDA; Shares Climb 3%	02/08/23	MT
PYC Therapeutics Completes Toxicology Testing of Retinitis Pigmentosa Medication	18/07/23	MT

Chart PYC Therapeutics Limited

Duration

Period

More charts

PYC Therapeutics Limited is an Australia-based clinical-stage biotechnology company creating a new generation of ribonucleic acid (RNA) therapies to change the lives of patients with genetic diseases. The Company utilizes its proprietary drug delivery platform to enhance the potency of precision medicines within the rapidly growing and commercially proven RNA therapeutic class. Its drug development programs target monogenic diseases - the indications with the highest likelihood of success in clinical development. Its first-in-class drug programs include Retinitis Pigmentosa type 11, (VP-001), Polycystic Kidney Disease, (PYC-003), Autosomal Dominant Optic Atrophy (ADOA) (PYC-001) and Phelan-McDermid Syndrome (PMS) (PYC-002). The Company's VP-001 program is a lead asset for a blinding eye disease of childhood progressed through multiple patient cohorts in the ongoing single ascending dose clinical trial. ADOA is a progressive and blinding eye disease.

Sector

Biotechnology & Medical Research

Calendar

26/08/2024 - Q4 2024 Earnings Release (Projected)

More about the company

Income Statement Evolution

More financial data

Ratings for PYC Therapeutics Limited

Trading Rating

Investor Rating

ESG Refinitiv

More Ratings

Analysts' Consensus

Sell

Buy

Mean consensus

BUY

Number of Analysts

Last Close Price

0.105 AUD

Average target price

0.2933 AUD

Spread / Average Target

+179.36%

Consensus

EPS Revisions

Estimates Revisions

Annual profits - Rate of surprise

Company calendar

Sector Other Biotechnology & Medical Research

	1st Jan change	Capi.
PYC THERAPEUTICS LIMITED	-4.55%	324M
MODERNA, INC.	+40.80%	53.67B
LONZA GROUP AG	+35.79%	38.86B
IQVIA HOLDINGS INC.	-8.05%	38.76B
CELLTRION, INC.	-8.98%	27.27B
ICON PUBLIC LIMITED COMPANY	+10.69%	25.91B
ALNYLAM PHARMACEUTICALS, INC.	-16.21%	20.29B
UNITED THERAPEUTICS CORPORATION	+31.00%	12.78B
MEDPACE HOLDINGS, INC.	+28.51%	12.18B
BIO-TECHNE CORPORATION	-1.67%	11.96B

Other Biotechnology & Medical Research

PYC Therapeutics Limited

Equities

PYC

AU000000PYC7

Biotechnology & Medical Research

Phylogica Ltd Appoints Dr. Bernard Hockings as Director

Latest news about PYC Therapeutics Limited

Chart PYC Therapeutics Limited

Company Profile

Income Statement Evolution

Ratings for PYC Therapeutics Limited

Analysts' Consensus

EPS Revisions

Annual profits - Rate of surprise

Sector Other Biotechnology & Medical Research